Company Description
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States.
The company develops an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome.
It is also developing three product candidates based on the whole proteome differential screening target discovery platform, including a malaria vaccine candidate against plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1) and/or against plasmodium falciparum Glutamic Acid Rich Protein (PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria product candidate targeting PfGARP.
The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | M. Berrey |
Contact Details
Address: 55 Claverick Street, Room 325 Providence, Rhode Island 02903 United States | |
| Phone | 401 444 7375 |
| Website | oceanbiomedical.com |
Stock Details
| Ticker Symbol | OCEA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001869974 |
| CUSIP Number | 67644P105 |
| ISIN Number | US67644C1045 |
| Employer ID | 87-1309280 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. M. Michelle Berrey M.D., M.P.H. | Chief Executive Officer and Director |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder and Executive Chairman of the Board |
| Dr. Jack A. Elias M.D. | Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Jonathan Kurtis M.D., Ph.D. | Founder, Chairman of Scientific Advisory Board and Director |
| Jolie G. Kahn CPA, Esq. | Chief Financial Officer |
| Robert John Sweeney | Chief Accounting Officer and Assistant Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 8-K | Current Report |